Scarica l'app Stockscreener
20.46
5.59%
0.9523
Precedente Chiudi:
$19.51
Aprire:
$19.59
Volume 24 ore:
2.06M
Relative Volume:
0.45
Capitalizzazione di mercato:
$1.27B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-5.22
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
-5.37%
1M Prestazione:
-31.06%
6M Prestazione:
+34.29%
1 anno Prestazione:
+33.77%
Intervallo 1D:
$19.29
$20.61
Intervallo di 1 settimana:
$19.29
$21.75
Portata 52W:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
20.45 | 1.22B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.88 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.59 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.05 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.50 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
(QURE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Stifel Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Price Target Lowered to $40.00 at Stifel Nicolaus - MarketBeat
Roku To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
uniQure (QURE) Price Target Lowered by Stifel Analyst | QURE Sto - GuruFocus
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Stempoint Capital LP Has $7.98 Million Stock Holdings in uniQure N.V. $QURE - MarketBeat
Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq
Mizuho Lowers Price Target for uniQure (QURE) to $33.00 | QURE S - GuruFocus
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Swiss National Bank Makes New Investment in uniQure N.V. $QURE - MarketBeat
uniQure NV (HAM:UQ1) Non Operating Income : €-3.54 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Total Long-Term Liabilities : €476.27 Mil (As of Sep. 2025) - GuruFocus
Voss Capital LP Takes $1.74 Million Position in uniQure N.V. $QURE - MarketBeat
Pale Fire Capital SE Boosts Stake in uniQure N.V. $QURE - MarketBeat
Progress on AMT-130 Halts uniQure N.V.’s (QURE) Downtrend - Insider Monkey
uniQure (NASDAQ:QURE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years – Company AnnouncementFT.com - Financial Times
Aug Wrap: Can uniQure NV stock surprise with earnings upside2025 Key Highlights & Smart Swing Trading Techniques - BỘ NỘI VỤ
uniQure (NASDAQ:QURE) Shares Down 5.1%Here's What Happened - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Your Wyoming Link
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat
How uniQure N.V. (UQ1) stock benefits from digital adoptionTrade Ideas & Scalable Portfolio Growth Methods - Newser
How strong is uniQure N.V. stock revenue growthJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser
uniQure (QURE) Is Down 17.3% After FDA Questions AMT-130 Data Sufficiency For BLAHas The Bull Case Changed? - simplywall.st
Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Enc - GuruFocus
uniQure (QURE) Stock: Navigates Regulatory Hurdles for AMT-130 as FDA Requests Further Engagement - parameter.io
uniQure (QURE) Analyst Ratings: Chardan Capital Maintains Buy Ra - GuruFocus
Why uniQure Stock Is Trading Lower After FDA Meeting Update - Sahm
uniQure N.V. (QURE): A Bear Case Theory - Finviz
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
uniQure (QURE) Shares Plunge 20% on FDA Feedback for AMT-130 - GuruFocus
uniQure says FDA announced Phase I/II AMT-130 data unlikely to support BLA - TipRanks
uniQure stock falls after FDA signals data unlikely to support AMT-130 approval - Investing.com Australia
uniQure stock falls after FDA's notes on pre application of AMT-130 - Seeking Alpha
uniQure (QURE) Reassesses Strategy After FDA Feedback on AMT-130 Application - GuruFocus
UniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission - marketscreener.com
Why Is UniQure Stock Falling In Pre-market? - Nasdaq
uniQure Faces Setback in Gene Therapy Approval - TipRanks
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - The Manila Times
uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView — Track All Markets
Uniqure N.V. Provides Regulatory Update on Amt-130 for Huntington's Disease - marketscreener.com
uniQure (NASDAQ: QURE) receives FDA minutes on AMT-130 BLA path for Huntington’s disease - Stock Titan
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Nov 06 '25 |
Sale |
27.26 |
31,434 |
856,881 |
40,145 |
| Kaye Jack | Director |
Nov 04 '25 |
Option Exercise |
9.88 |
38,810 |
383,535 |
38,249 |
| Kaye Jack | Director |
Nov 04 '25 |
Sale |
30.34 |
38,810 |
1,177,517 |
20,439 |
0.56%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):